Biocomposites, a medical devices company, completed the acquisition of Artoss, a specialist manufacturer of innovative bone graft. Financial terms were not disclosed. “We are delighted to have completed this acquisition of Artoss. Adding the NanoBone range of products to our portfolio provides us with a new differentiated offering to help surgeons treat their patients and a platform from which to develop new ready-to-use products. Following on from our acquisitions of Subiton and Synimed last year, we have established ourselves as the go-to provider for surgeons requiring bone regeneration and/or managing infection in bone and soft tissue," Michael Harris, Biocomposites CEO.